Tazobactam Sodium | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Tazobactam Sodium
US Exclusivities

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Tazobactam Sodium

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 16 USDMF, 9 JDMF, 4 EU WC, 2 KDMF, 10 NDC API, 7 Listed Suppliers, $ API Reference Price

28 API Suppliers
16 USDMF
9 JDMF
4 EU WC
2 KDMF
10 NDC API
7 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

124 FDF Dossiers, 57 FDA Orange Book, 30 Europe, 9 South Africa, 28 Listed Dossiers

124 FDF Dossiers
57 FDA Orange Book
30 Europe
9 South Africa
28 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML, INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML, INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML
INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML
INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 1 Faran Shimi Pharmaceutical, 1 Pfanstiehl, 3 Actylis, 1 Pluviaendo, 4 Roquette

1 SPI Pharma
1 Faran Shimi Pharmaceutical
1 Pfanstiehl
3 Actylis
1 Pluviaendo
4 Roquette

EXCIPIENTS BY APPLICATIONS

6 Parenteral, 2 Fillers, Diluents & Binders, 1 Thickeners and Stabilizers, 1 API Stability Enhancers

6 Parenteral
2 Fillers, Diluents & Binders
1 Thickeners and Stabilizers
1 API Stability Enhancers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 42 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
42 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

28 Finished Drug Prices, 5 Annual Reports

28 Finished Drug Prices
5 Annual Reports

MARKET PLACE

14 APIs, 5 FDF Dossiers

14 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

28 US Patents, 3 US Exclusivities

28 US Patents
3 US Exclusivities

REF. STANDARDS & IMPURITIES

1 USP, 2 Others

1 USP
2 Others

$ API Ref.Price (USD/KG) : 135 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

3 All

01 3CUBIST PHARMS LLC

filter Product Reset all filters

3 All

01 3CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

filter Exclusivity Expiration Date Reset all filters

3 All

01 12019-12-19

02 12024-12-19

03 12025-04-21

filter Exclusivity Code Reset all filters

3 All

01 1GAIN

02 1NCE

03 1NPP

Product Main Page

CUBIST PHARMS LLC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Portfolio PDF

Product Web Link

Digital Content

Website

Corporate PDF

Exclusivity Code

GAIN

Exclusivity Expiration Date

2024-12-19

Application Number

206829

Product Number

1

Exclusivity Details

01

CUBIST PHARMS LLC

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

BioAsia

Not Confirmed

CUBIST PHARMS LLC

Switzerland

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Exclusivity Code : GAIN

Exclusivity Expiration Date : 2024-12-19

Application Number : 206829

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Website

Corporate PDF

CUBIST PHARMS LLC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Portfolio PDF

Product Web Link

Digital Content

Website

Corporate PDF

Exclusivity Code

NPP

Exclusivity Expiration Date

2025-04-21

Application Number

206829

Product Number

1

Exclusivity Details

02

CUBIST PHARMS LLC

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

BioAsia

Not Confirmed

CUBIST PHARMS LLC

Switzerland

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Exclusivity Code : NPP

Exclusivity Expiration Date : 2025-04-21

Application Number : 206829

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Website

Corporate PDF

CUBIST PHARMS LLC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Portfolio PDF

Product Web Link

Digital Content

Website

Corporate PDF

Exclusivity Code

NCE

Exclusivity Expiration Date

2019-12-19

Application Number

206829

Product Number

1

Exclusivity Details

03

CUBIST PHARMS LLC

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

BioAsia

Not Confirmed

CUBIST PHARMS LLC

Switzerland

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Exclusivity Code : NCE

Exclusivity Expiration Date : 2019-12-19

Application Number : 206829

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!